 Thank you. Taiwan is a small country, a small island, but has a dense population. And our national HEOC Institute covers more than 99% of the population. And our medical services have a very high quality but a very cheap price. Taiwan has a SCAR consortium formed by a physician from a different medical center. For example, Chang'e Memorial Hospital is the first initial sign we include patients. And this hospital system has more than 10,000 beds. And Taiwan has a Taiwan Drug Relief Foundation. This foundation is under control for Taiwan FDM. And they have a founding rights founder from a pharmaceutical company. According to this table, you can find that SSS and TEN accounts for more than 50% of the cases report to the Taiwan Adverse Drug Relief Foundation. And we have a very good connection with SCAR starting group in the world. And Taiwan SCAR consortium joined the Regis SCAR consortium since 2007. The most common drug associated with SCAR in Taiwan, they are areoprinofinitoy in the Kamazan Pin. And we analyze the anti-Kamazan drug associated with SCAR in Taiwan. And we can find out the Kamazan Pin, we can enjoy more than about 90 patients with Kamazan Pin induced SCAR. And most of them are SSS and TEN and very, very few are drugs. Other aromatic anti-conversants such as phenytoin, namotrogen also associated with SCAR. But the drug, the drug of Kamazan Pin, it has a similar structure with Kamazan Pin but the incidence of Kamazan Pin induced SCAR reaction is the incidence is very low in Taiwan. We use a candidate gene approach and identify actual B1502 is strongly associated with Kamazan Pin induced SSS and TEN. The associated strengths is very strong but the PPV, the positive and positive value is very low. And this special idea is associated only, associated with only Kamazan Pin induced SSS and TEN but not drugs. In our previous study, we can find that HRLA3101 associated with another phenotype non-breast reaction. But the associated strengths is not so strong as that of Kamazan Pin induced SSS and TEN. We collaborate with Regis SCAR and confirm the HRLA association is phenotype specific and HRLA3101 associated with Kamazan Pin induced drugs. And in year 2011, a prospective screen of HRLA B1502 in Taiwan, led by Akademiya Shinika and we enrolled about 5,000 patients and performed a genotyping before prescribing Kamazan Pin. And on this paper, we showed that there was no SSS and TEN case. So Taiwan government decides to cover the expense of HRLA B type for Kamazan Pin new user since year 2010. And so nowadays, there is a routine test for HRLA B1502 genotyping before the patient using Kamazan Pin. So this is an example for the genetic test. The physician, they can receive such as the report and they also can receive the report from the self-frontation. And another example is that we report HRLA B1501 strongly associated with Ropino SCAR. And we also can find that the associated strengths are very strong. But PVV is also very low, only 3%. It means that most of the HRLA B1502 carrier in our population, for example, about 15%, they are towards Ropino. So we have another study to find out what is the non-genetic factor. We find that if the patient, they have an old age and with a renal insufficiency, then many of such patients, they have a higher past medical level of aspirin. Because the aspirin is the main metabolite of our aspirin, and you can find that if the patient has a renal deficiency and a chronic kidney disease, then the patient, they have a higher past medical level of aspirin. So nowadays, many physicians in Taiwan, they can perform the genetic test for the patient, but for all of the patients in some hospitals, some hospitals, they only provide a service for the patient with high risk. And we also report that HRLA B1502 is weakly associated with phenytoin-induced SZS and TM, the aspirin is only 5%. So we have another study published last year, reporting that phenytoin-redeuska is associated with centricone P450-2C19. And this study was collaborated with the Japanese and Malaysia, and the association has been verified in these two populations. And the P-value is also very significant, but the ulceration is about 12. And in the plasma sample, you can find that the patients have a delay of phenytoin in the scar patient, especially in the SZS and TM patients. And we can find the delay clinics of phenytoin in the patient carry a risk allele. And some patients, they did not carry the risk allele, but they also have a delay clinics of the plasma phenytoin. It is possible that the patients have a liver disease or kidney disease. And we also have some study for the plasma mechanism. And we report that granitine is a chemediator for the skin deaths in SZS and TM. We suggest that granitine could be a chemediator. And we use granitine as a disease target. And we perform some in vitro study and suggest that granitine could be a disease target. And we study the H-R-H drug and peptide T-cell receptor interaction. We report that there is no peptide change in the presence of chamoisampines. But the specific associated H-R-B allele, they can have a higher affinity with the drug. Such as chamoisampines or the metabolite. But not have affinity to the chamoisampines. This is the metabolite of chamoisampines. And we have identified some sign, could be the drug binding sign. And we report that several specific T-cell receptor may be involved in such kind of immuno-reaction. For the European case, we report that Ospirino is the antigen of T-cell. And we identify some mutation side. Some specific side of H-R-B-15-L-1 is specific media to the drug presentation. So there are many factors that can contribute to SCAR. In addition to the H-R-O-A, the metabolite gene is also very important for SCAR. And also the concentration of the active metabolite or the drug-drug interaction is also involved in the SCAR. And for the mechanism, some H-R-O-A may have a higher affinity to the drug. But that should need the help of a T-cell receptor. And other factors such as the environmental pathogen may cause the key point for the initiation of the immuno-reaction. Thank you very much for your attention. Thank you very much for that summary. Are there questions or comments? Do you know what the metabolite is? That's binding to the MHC? Binding to the MHC. So the metabolite, you did some H-B-L-C, I assume. We analyzed the peptide. But the peptide repertoire has no change in the presence of the kamalampin or the metabolite. And if you ask why is the metabolite binding to the MHC, we have some metabolite and the seminal drug such as phenytoin or lamotrigium. But the higher affinity can only be observed in kamalampin and the apple-side kamalampin. But we did not observe affinity in the kamalampin. That's the metabolite of osteo-kamalampin. Mark Williams, Geisinger. This is actually a question from Maya related to the CIP-2C9-STAR-3. Because my recollection from the JAMA paper is that that allele frequency in the ancestral population that you studied is quite low, where it's somewhat more frequent in the northern European population. So it's raised a question in terms of whether there is a risk for phenytoin in Caucasians that are more likely to carry the 2C9-STAR-3. And I was wondering if the EuroSCAR has looked at that specific question to determine whether there is a difference that can be detected. We're working on that currently, but I cannot tell you a result yet. Other questions or comments? Yes. Is there a diagnostic test that takes advantage of the information you've learned about granulicin and the T-cell receptor that could be used to more definitively ascertain who will go on to develop STST? For granulicin, because granulicin is a pretense in our blood in healthy patients. If some patient you have a doubt, maybe he will develop STS or MPE, macular population or DRACE, then you can extend the blood level of granulicin. Sometimes the granulicin level is increased only in STS and TEM, but not in DRACE or MPE. For the usage of T-cell receptor in clinical, because now that we use NGS to study T-cell receptor, we can find why the T-cell receptor is one individual. It is possible that you can use such a specific T-cell receptor type to suggest why the risk of the patient is. But now that we find more than one, then about 10 specific T-cell receptor types are associated with such kind of disease. So it may be very complicated that you may not save if you only use one or two T-cell type. Thank you. I think we're going to have to move on. Thank you very much. Next, going back to Europe. I assume England is still considered Europe, even though they're not Euro mode. Dr. Pirma Mohamed from the University of Liverpool, the Weatherall Chair of Medicine in Liverpool.